194 related articles for article (PubMed ID: 23548992)
1. Metastatic bone disease in the era of bone-targeted therapy: clinical impact.
Ibrahim T; Farolfi A; Mercatali L; Ricci M; Amadori D
Tumori; 2013; 99(1):1-9. PubMed ID: 23548992
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
3. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Saba N; Khuri F
Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
5. [Management of bone metastases].
Nagykálnai T; Landherr L
Orv Hetil; 2014 Feb; 155(6):217-25. PubMed ID: 24486845
[TBL] [Abstract][Full Text] [Related]
6. [Bone metastases in lung cancer].
Tsuya A; Fukuoka M
Clin Calcium; 2008 Apr; 18(4):455-9. PubMed ID: 18379026
[TBL] [Abstract][Full Text] [Related]
7. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Graff JN; Beer TM
Oncology (Williston Park); 2015 Jun; 29(6):416-23. PubMed ID: 26091674
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Diel IJ; Solomayer EF; Bastert G
Clin Breast Cancer; 2000 Apr; 1(1):43-51. PubMed ID: 11899389
[TBL] [Abstract][Full Text] [Related]
9. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
10. [Role of bone-density-conserving agents in the treatment for pain in patients with bone metastases].
Zhabina AS; Semiglazova TY
Vopr Onkol; 2015; 61(2):303-10. PubMed ID: 26087615
[TBL] [Abstract][Full Text] [Related]
11. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.
Broder MS; Gutierrez B; Cherepanov D; Linhares Y
Support Care Cancer; 2015 Jan; 23(1):237-47. PubMed ID: 25270847
[TBL] [Abstract][Full Text] [Related]
12. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
13. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
15. Metastatic bone disease and tumour-induced hypercalcaemia: treatment options.
Heatley S
Int J Palliat Nurs; 2004 Jan; 10(1):41-6. PubMed ID: 14966444
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Major PP; Cook R
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Guida A; Albiges L
Bull Cancer; 2018 Dec; 105 Suppl 3():S268-S279. PubMed ID: 30595156
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
19. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Saad F; Eastham J
Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
